Vertex Pharmaceuticals Povetacicept BAFF/APRIL-Blocking Fusion Protein for Primary IgA Nephropathy Has FDA BLA Acceptance With PDUFA Target Action Date November 30, 2026: Phase 3 Topline Data From March Showed 49.8% Reduction in Urine Protein-Creatinine Ratio at 36 Weeks Versus Placebo; BioSpace Analysis Characterizes the Program as Derisked After the Vera Therapeutics July 7 TRUTAKNA and Novartis July 17 Fabhalta Approvals in the Same Indication
Vertex Pharmaceuticals' (NASDAQ: VRTX) povetacicept, a BAFF/APRIL-blocking fusion protein for primary IgA nephropathy, has US FDA acceptance of its Biologics License Application with a PDUFA target action date of November 30, 2026. Povetacicept works through the same mechanism as Vera Therapeutics' TRUTAKNA (atacicept-vymj), targeting the BAFF and APRIL cytokines that drive plasma-cell antibody production. Phase 3 topline data reported in March 2026 showed a 49.8% reduction in urine protein-creatinine ratio (UPCR) at 36 weeks in povetacicept-treated patients versus placebo (versus 45.7% for TRUTAKNA in the ORIGIN Phase 3). BioSpace analysis published this weekend characterizes the Vertex program as derisked following the Vera TRUTAKNA approval on July 7 and the Novartis Fabhalta traditional approval on July 17 — both marketing campaigns will build IgAN awareness and educate nephrologists on the treatment landscape before povetacicept reaches market, and both approvals validate the FDA's willingness to green-light novel IgAN mechanisms on accelerated pathways. Povetacicept, if approved, would become the first commercialized therapy in Vertex's emerging nephrology franchise.